From: Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs
Case | Histrogical type | EGFR mutation status | Brinkman index | Treatment agent | Response | IL-8 (ng/mL) | IL-10 (ng/mL) | RANTES (pg/ml) |
---|---|---|---|---|---|---|---|---|
1 | Ad | Ex21 L858R | 900 | gefitinib | PR | 5.79 | 1.67 | 2 |
2 | Ad | Ex21 L858R | 0 | erlotinib | PR | 3.33 | 94.2 | 1.41 |
3 | Ad | Ex19 del | 0 | erlotinib | PR | 4.09 | 126 | 2.13 |
4 | Ad | Ex21 L858R | 0 | gefitinib | PR | 3.92 | 18.1 | 1.85 |
5 | Ad | Ex21 L858R + Ex19 del | 370 | erlotinib | PR | 21.9 | 1.23 | 2.11 |
6 | Ad | Ex19 del | 0 | erlotinib | PR | 7.05 | 1.37 | 2.56 |
7 | Ad | Ex19 del | 0 | gefitinib | PR | 4.82 | 1.59 | 2.02 |
8 | Ad | Ex21 L858R | 1640 | gefitinib | PR | 54.9 | 2.7 | 2.38 |
9 | Ad | negative | 400 | erlotinib | SD | 34.9 | 3.39 | 3.66 |
10 | Ad | negative | 0 | erlotinib | SD | 27.1 | 4.94 | 2.25 |
11 | Ad | unknown | 1800 | erlotinib | SD | NE | NE | NE |
12 | Sq | Ex19 del | 3840 | gefitinib | SD | 12.6 | 1.1 | 1.98 |
13 | Ad | Ex19 del | 30 | erlotinib | SD | 5.27 | 0.69 | 2.66 |
14 | Ad | Ex19 del | 0 | erlotinib | SD | 10.5 | 0.85 | 2.5 |
15 | Ad | unknown | 300 | erlotinib | SD | 7.69 | 2.61 | 1.7 |
16 | La | negative | 2080 | erlotinib | SD | NE | NE | NE |
17 | Sq | Ex21 L858R | 750 | erlotinib | SD | 11.6 | 56.3 | 3.06 |
18 | Ad | unknown | 600 | erlotinib | SD | 13.7 | 1.1 | 2.82 |
19 | Ad | Ex21 L858R | 0 | erlotinib | SD | 20.6 | 11.6 | 0.783 |
20 | Ad | Ex19 del | 0 | erlotinib | SD | 14.8 | 2.07 | 2.02 |
21 | Ad | Ex21 L858R + Ex19 del | 0 | gefitinib | SD | 3.04 | 1.3 | 1.76 |
22 | Ad | Ex19 del | 200 | gefitinib | SD | 10.9 | 1.59 | 1.91 |
23 | Sq | unknown | 1560 | erlotinib | PD | NE | NE | NE |
24 | Ad | negative | 1080 | erlotinib | PD | 25.2 | 8.15 | 1.57 |
25 | Ad | unknown | 0 | erlotinib | PD | NE | NE | NE |
26 | Ad | Ex18 G719A | 2000 | erlotinib | PD | 11.6 | 4.48 | 3.12 |
27 | Ad | unknown | 1410 | erlotinib | PD | NE | NE | NE |
28 | Ad | Ex19 del | 1000 | gefitinib | PD | 9.44 | 2.25 | 2.89 |
29 | Ad | negative | 1100 | erlotinib | PD | 56.3 | 5.63 | 2.16 |
30 | Ad | negative | 2000 | erlotinib | PD | 15.6 | 0.85 | 0.292 |
31 | Ad | negative | 825 | erlotinib | PD | 8.27 | 1.59 | 2.13 |
32 | Ad | Ex21 L858R | 0 | erlotinib | PD | 5.34 | 7.05 | 1.7 |
33 | Ad | negative | 1680 | erlotinib | PD | 57.7 | 1.63 | 2.06 |